FI964681A - Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt - Google Patents

Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt Download PDF

Info

Publication number
FI964681A
FI964681A FI964681A FI964681A FI964681A FI 964681 A FI964681 A FI 964681A FI 964681 A FI964681 A FI 964681A FI 964681 A FI964681 A FI 964681A FI 964681 A FI964681 A FI 964681A
Authority
FI
Finland
Prior art keywords
lactobacillus strains
human origin
preparations containing
lactobacillus
strains
Prior art date
Application number
FI964681A
Other languages
English (en)
Swedish (sv)
Other versions
FI964681A0 (fi
FI119059B (fi
Inventor
Lorenzo Morelli
Vittorio Bottazzi
Luigia Gozzini
Haen Christoph De
Original Assignee
Bracco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26331139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI964681(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITMI941073A external-priority patent/IT1269838B/it
Priority claimed from ITMI941773A external-priority patent/IT1274733B/it
Application filed by Bracco Spa filed Critical Bracco Spa
Publication of FI964681A0 publication Critical patent/FI964681A0/fi
Publication of FI964681A publication Critical patent/FI964681A/fi
Application granted granted Critical
Publication of FI119059B publication Critical patent/FI119059B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI964681A 1994-05-26 1996-11-25 Ihmisestä peräisin olevat Lactobacillus-kannat, niiden koostumukset ja niiden käytöt FI119059B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ITMI941073A IT1269838B (it) 1994-05-26 1994-05-26 Ceppi di lattobacilli di origine umana e loro usi
ITMI941073 1994-05-26
ITMI941773A IT1274733B (it) 1994-08-25 1994-08-25 Ceppo del genere lactobacillus di origine umana e suoi usi
ITMI941773 1994-08-25
PCT/EP1995/001886 WO1995033046A1 (en) 1994-05-26 1995-05-18 Lactobacillus strains of human origin, their compositions and uses thereof
EP9501886 1995-05-18

Publications (3)

Publication Number Publication Date
FI964681A0 FI964681A0 (fi) 1996-11-25
FI964681A true FI964681A (fi) 1997-01-08
FI119059B FI119059B (fi) 2008-07-15

Family

ID=26331139

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964681A FI119059B (fi) 1994-05-26 1996-11-25 Ihmisestä peräisin olevat Lactobacillus-kannat, niiden koostumukset ja niiden käytöt

Country Status (18)

Country Link
US (1) US5709857A (fi)
EP (1) EP0760848B1 (fi)
JP (1) JP3653277B2 (fi)
CN (1) CN1094972C (fi)
AT (1) ATE163042T1 (fi)
AU (1) AU686389B2 (fi)
BR (1) BR9507752A (fi)
CA (1) CA2191213C (fi)
DE (2) DE760848T1 (fi)
DK (1) DK0760848T3 (fi)
ES (1) ES2099056T3 (fi)
FI (1) FI119059B (fi)
GR (2) GR970300016T1 (fi)
HU (1) HU220190B (fi)
MX (1) MX9605807A (fi)
NO (1) NO316644B1 (fi)
NZ (1) NZ287420A (fi)
WO (1) WO1995033046A1 (fi)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN175495A0 (en) 1995-03-14 1995-04-13 University Of New England, The Method and composition for the prevention of the over production of acid
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
IT1289159B1 (it) * 1997-01-08 1998-09-29 Yurta S R L Composizioni farmaceutiche e alimentari a base di batteri del genere acetobacter
IT1289984B1 (it) * 1997-02-27 1998-10-19 Proge Farm Srl Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale
IT1299070B1 (it) * 1998-04-10 2000-02-07 Proge Farm Srl Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e
US7202219B1 (en) * 1998-02-24 2007-04-10 Md Foods Amba Use of D-tagatose as a prebiotic food component
DK0956858T3 (da) 1998-04-30 2002-01-28 Vesely Renata Maria Cavaliere Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
EP1034787A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
EP1034788A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
CZ20013269A3 (cs) * 1999-03-11 2002-04-17 Société des Produits Nestlé S. A. Bakterie mléčného kvaąení
US20040105848A1 (en) * 1999-04-30 2004-06-03 Natarajan Ranganathan Enteric dialysis compositions and methods
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20040166101A1 (en) * 1999-09-22 2004-08-26 Bojrab Gregory G. Enchanced composition for treatment of gastrointestinal disorders and hyperlipidemia
US6641808B1 (en) 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6613549B2 (en) 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
DE60137334D1 (de) * 2000-06-09 2009-02-26 Baylor College Medicine Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
MXPA03005465A (es) 2000-12-18 2004-10-14 Probiohealth Llc Compuestos probioticos derivados de la cepa ke01 de lactobacillus casei.
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
NO318426B1 (no) * 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
US8147821B2 (en) * 2002-02-21 2012-04-03 Grain Processing Corporation Method for drying biomaterials
DE60323734D1 (de) 2002-03-21 2008-11-06 Bifodan As Lactobacillus-stämme
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
CA2547144C (en) 2005-05-16 2010-02-02 Grain Processing Corporation Method for drying spent filter media
CN101273738B (zh) * 2007-03-28 2011-06-01 哈尔滨正方科技有限公司 在常温下保持高活菌数的调配型酸性乳饮料的制备方法
PL2016834T3 (pl) * 2007-07-13 2010-04-30 Unilever Nv Produkt żywnościowy zawierający bakterie i sorbitolowy ester kwasu tłuszczowego
US20090041727A1 (en) * 2007-08-08 2009-02-12 Conjugon, Inc. Compositions and Methods for Microbe Storage and Delivery
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US20110189148A1 (en) * 2008-06-25 2011-08-04 Ritter Pharmaceuticals, Inc. Lactose compositions with decreased lactose content
KR101003149B1 (ko) * 2008-10-31 2010-12-22 전남대학교산학협력단 병변 치료용 박테리아 기반의 마이크로로봇
EP2206506A1 (en) 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotic formulations
CA2984935C (en) 2009-02-24 2021-01-12 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2248908A1 (en) 2009-05-05 2010-11-10 Eurolactis Group S.A. Probiotic microorganisms isolated from donkey milk
WO2011009848A2 (en) 2009-07-20 2011-01-27 Bracco Spa Therapeutic use of probiotics
EP3202406A1 (en) * 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012122478A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
BR112015006568B1 (pt) * 2012-09-25 2022-07-05 Aquilon Cyl S.L. Uso de uma composição e composição
JP6692897B2 (ja) 2015-05-14 2020-05-13 クレストヴォ・ホールディングス・エルエルシー 便フローラを移植するための組成物、並びにそれを調製及び使用する方法、並びにそれを送達するためのデバイス
CN114470009A (zh) 2015-05-22 2022-05-13 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
AU2018250206A1 (en) 2017-04-05 2019-10-31 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (PD) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
AU2018313766A1 (en) 2017-08-07 2020-02-20 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US4946791A (en) * 1986-10-02 1990-08-07 Bio Techniques Laboratories, Inc. Novel strain of Lactobacillus acidophilus
US5179020A (en) * 1991-08-19 1993-01-12 Bio Techniques Laboratories, Inc. Antibiotic resistant strain of lactobacillus acidophilus
DE69219768T2 (de) * 1992-07-06 1997-08-28 Societe Des Produits Nestle S.A., Vevey Milchbakterien

Also Published As

Publication number Publication date
MX9605807A (es) 1997-12-31
FI964681A0 (fi) 1996-11-25
EP0760848A1 (en) 1997-03-12
AU2613995A (en) 1995-12-21
GR970300016T1 (en) 1997-05-31
CA2191213A1 (en) 1995-12-07
ATE163042T1 (de) 1998-02-15
FI119059B (fi) 2008-07-15
CN1094972C (zh) 2002-11-27
NO964966L (no) 1997-01-23
DE760848T1 (de) 1997-08-28
CA2191213C (en) 2008-03-18
CN1154715A (zh) 1997-07-16
DE69501591T2 (de) 1998-06-10
DK0760848T3 (da) 1998-09-23
HU220190B (hu) 2001-11-28
DE69501591D1 (de) 1998-03-12
GR3026758T3 (en) 1998-07-31
NO964966D0 (no) 1996-11-22
EP0760848B1 (en) 1998-02-04
ES2099056T3 (es) 1998-04-01
US5709857A (en) 1998-01-20
WO1995033046A1 (en) 1995-12-07
JP3653277B2 (ja) 2005-05-25
BR9507752A (pt) 1997-10-07
NZ287420A (en) 1997-12-19
NO316644B1 (no) 2004-03-22
JPH10500577A (ja) 1998-01-20
AU686389B2 (en) 1998-02-05
ES2099056T1 (es) 1997-05-16
HU9603251D0 (en) 1997-01-28
HUT75555A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
FI964681A (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69905170D1 (en) Thiazolopyrimidinderivate
BG102781A (en) Isolated dimer fibroblastactivation protein alpha and its application
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
BG100248A (en) Squalene synthetase inhibitors
ATE28188T1 (de) Antikonvulsive mittel.
AU6849198A (en) Neurotrypsin
AU580890B2 (en) P-acylaminobenzamides
BG104452A (en) New derivatives of the methylenebisphosphonic acid
MD980129A (en) Antiherpetic remedy
MX9708385A (es) Derivados novedosos de tetraciclina, composiciones que los contienen, y el uso de las mismas.
UA26246C2 (uk) Коhтрацептивhий комбіhоваhий препарат
IT1269740B (it) Derivati di combretastatine ad attivita' anti-tumorale e procedimento per la loro preparazione
MX9706412A (es) Uso de aerogeles inorganicos en la industria farmaceutica.

Legal Events

Date Code Title Description
MM Patent lapsed